1/5
Amberen
Amberen Advanced Perimenopause Relief Capsules
60 ct
$31.15 each($0.52 / ct)
Aisle 34
Victoria H‑E‑B plus!
6106 N. NAVARRO
Description
Our extensively researched ingredients target 10 perimenopause symptoms which include fatigue, irritability, sleeplessness, anxiety and stress, hot flashes, night sweats, muscle and joint aches, headaches, mood swings, and low sex drive. Amberen works hard to relieve most common perimenopause symptoms so that you can get back to enjoying your life again.
Nutrition Facts
Purple Capsule30 servings per container
Serving Size2.00 Capsules (1 white and 1 purple)- % Daily Value*
- Vitamin E
- 5.04mg
- 34%
- Vitamin B12
- 2mcg
- 83%
- Vitamin B6
- 2mg
- 118%
Nutrition Facts
White Capsule0 servings per container
Serving Size0.00- Amount Per ServingCalories0
Ingredients
Amberen is Formulated with Smart-B Complex, Our Unique Blend of B-Vitamins, Plus Our Proprietary Compound of Bioactive Antioxidants, Amino Acids, Minerals and Vitamin E. Other Ingredients: Gelatin, White Rice Flour, Magnesium Stearate, Silicon Dioxide, Titanium Dioxide, FD&C Red40, FD&C Blue1, FD&C Red 3 and Water. Amberen Perimenopause Proprietary Compound: Ammonium Succinate, Disodium Fumarate, Calcium Disuccinate, Monosodium L-Glutamate, Glycine, Magnesium Disuccinate, Zinc Difumarate.Allergens and safety warnings
Notice: Women in perimenopause can become pregnant, discuss contraception options with your doctor. In a clinical trial a statistically significant number of Amberen group participants reported a return of their period to a more regular pattern. Caution: As with any dietary supplement, consult your doctor before use if you are taking a prescription medication or have a medical condition. Do not take if pregnant or nursing. Do not take if you have severe hypertension. Keep out of reach of children. Use only as directed.- Directions: Take 1 white and 1 purple capsule daily after first meal. Clinically recommended to be used for at least 90 days (Based on results of 180-day placebo-controlled clinical trial involving 105 perimenopausal women aged 36-50 with mild to moderate symptoms).